REGENXBIO

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. 

CEO
Curran M. Simpson
CEOCurran M. Simpson
Employees
371
Employees371
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2008
Founded2008
Employees
371
Employees371

RGNX Key Statistics

Market cap
622.53M
Market cap622.53M
Price-Earnings ratio
-1.74
Price-Earnings ratio-1.74
Dividend yield
Dividend yield
Average volume
2.22M
Average volume2.22M
High today
$10.34
High today$10.34
Low today
$9.57
Low today$9.57
Open price
$10.24
Open price$10.24
Volume
966.58K
Volume966.58K
52 Week high
$16.19
52 Week high$16.19
52 Week low
$5.46
52 Week low$5.46

Stock Snapshot

The current REGENXBIO(RGNX) stock price is $9.73, with a market capitalization of 622.53M. The stock trades at a price-to-earnings (P/E) ratio of -1.74.

As of 2026-07-25, REGENXBIO(RGNX) stock has fluctuated between $9.57 and $10.34. The current price stands at $9.73, placing the stock +1.7% above today's low and -5.9% off the high.

The REGENXBIO(RGNX)'s current trading volume is 966.58K, compared to an average daily volume of 2.22M.

During the past year, REGENXBIO(RGNX) stock moved between $5.46 at its lowest and $16.19 at its peak.

During the past year, REGENXBIO(RGNX) stock moved between $5.46 at its lowest and $16.19 at its peak.

RGNX News

Benzinga 5d
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Benzinga

...

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Benzinga
TipRanks 5d
RegenXBio Raises Capital Through Public Equity Offering

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 6d
Regenxbio presents long-term data for surabgene lomparvovec

Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal delivery and diab...

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

People also own

Based on the portfolios of people who own RGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.